Oxytocin in the heart regeneration

Recent Patents on Cardiovascular Drug Discovery

Volumn 7, Issue 2, 2012, Pages 81-87

  Jankowski, Marek ^a   Gonzalez Reyes, Araceli ^a   Noiseux, Nicolas ^b   Gutkowska, Jolanta ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(2,4 DIISOLEUCINE) OXYTOCIN; 4 THREONINE 1 HYDROXY DEAMINOOXYTOCIN; 7 DEXTRO PROLINE OXYTOCIN; 9 DEAMIDOOXYTOCIN; CARBETOCIN; DEMOXYTOCIN; NUCLEIC ACID; OXYTOCIN; UNCLASSIFIED DRUG; VASOPRESSIN;

CELL DIFFERENTIATION; DIABETES INSIPIDUS; DRUG MECHANISM; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; NONHUMAN; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS; SHOCK; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; UTERINE ATONY;

ANIMALS; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HUMANS; MODELS, CARDIOVASCULAR; MUSCLE DEVELOPMENT; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; OXYTOCIN; REGENERATION; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84863543680     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489012801227210     Document Type: Review

References (65)

1. Jankowski M, Hajjar F, Kawas SA, Mukaddam-Daher S, Hoffman G, McCann SM, et al. Rat heart: A site of oxytocin production and action. Proc Natl Acad Sci USA 1998; 95:14558-63.
2. Brownstein MJ, Russell JT, Gainer H. Synthesis, transport, and release of posterior pituitary hormones. Science 1980; 207(4429): 373-8.
3. Burbach JP, Luckman SM, Murphy D, Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 2001; 81(3): 1197-267.
4. Morris M, Castro M, Rose JC. Alterations in oxytocin prohormone processing during early development in the fetal sheep. Am J Physiol 1992; 263(3 Pt 2): R738-40.
5. Alstein M, Whitnall MH, House S, Key S, Gainer H. An immunochemical analysis of oxytocin and vasopressin prohormone processing in vivo. Peptides 1988; 9(1): 87-105.
6. Altstein M, Gainer H. Differential biosynthesis and posttranslational processing of vasopressin and oxytocin in rat brain during embryonic and postnatal development. J Neurosci 1988; 8(11): 3967-77.
7. Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biological Psychiatry 2001; 50(8): 609-13.
8. Sirigu, A., Andari, E. Oxytocin treatment for behavioral characteristics associated with autism and Shyness disorder. WO2011027060 (2011).
9. Gimpl G, Fahrenholz F. The oxytocin receptor system: Structure, function and regulation. Physiologic Rev 2001; 81(2): 629-83.
10. Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci USA 1997; 94(21): 11704-9.
11. Florian M, Jankowski M, Gutkowska J. Oxytocin increases glucose uptake in neonatal rat cardiomyocytes. Endocrinology 2010; 151(2): 482-91.
12. Gimpl G. Oxytocin receptor ligands: a survey of the patent literature. Expert Opin Therapeut Pat 2008; 18(11): 1239-51.
13. Cort J, Barth T, Jost K, Veznik Z. Long-acting oxytocin analogs for use in inducing and accelerating labor in animals, particularly farm animals. US4237119 (1979).
14. Larsen, F. Effervescent formulations for oxytocin. US20060034920 (2006).
15. Flouret, G, Wilson, L. Oxytocin antagonist. US5373089 (1994).
16. Kuczynski, W., Pierzynski, P. Use of antagonists of oxytocin and/or vasopressin in assisted reproduction. WO2006121362 (2006).
17. Winikoff B, Dabash R, Durocher J, Darwish E, Nguyen TN, Leon W, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. Lancet 2010; 375(9710): 210-6.
18. Dyer RA, Butwick AJ, Carvalho B. Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist. Current Opin Anaesthesiol 2011; 24(3): 255-61.
19. Gutkowska J, Jankowski M. Oxytocin revisited: It is also a cardiovascular hormone. J Am Soc Hypertens 2008; 2(5): 318-25.
20. McCann SM, Antunes-Rodrigues J, Jankowski M, Gutkowska J. Oxytocin, vasopressin and atrial natriuretic peptide control body fluid homeostasis by action on their receptors in brain, cardiovascular system and kidney. Prog Brain Res 2002; 139: 309- 28.
21. Gutkowska J, Jankowski M, Mukaddam-Daher S, McCann SM. Oxytocin is a cardiovascular hormone. Brazilian J Med Biologic Res 2000; 33(6): 625-33.
22. Jankowski M, Danalache B, Wang D, Bhat P, Hajjar F, Marcinkiewicz M, et al. Oxytocin in cardiac ontogeny. Proc Natl Acad Sci USA 2004; 101(35): 13074-9.
23. Danalache BA, Paquin J, Donghao W, Grygorczyk R, Moore JC, Mummery CL, et al. Nitric oxide signaling in oxytocin-mediated cardiomyogenesis. Stem Cells 2007; 25(3): 679-88.
24. Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J. Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc Natl Acad Sci USA 2002; 99(14): 9550-5.
25. Gutkowska, J., Paquin, J., Danalache, B.A., Jankowski, M. Oxytocin as cardiomyogenesis inducer and uses thereof. US20060205636A1 (2006).
26. Uvas-Moberg, K., Lundeberg, T. Use of substances with oxytocin activity in order to create cell regeneration. EP1115416(2008).
27. Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011; 108(8): 1017-36.
28. Mukaddam-Daher S, Yin YL, Roy J, Gutkowska J, Cardinal R. Negative inotropic and chronotropic effects of oxytocin. Hypertension 2001; 38(2): 292-6.
29. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 2011; 90(2): 224-33.
30. Gutkowska J, Paquette A, Wang D, Lavoie JM, Jankowski M. Effect of exercise training on cardiac oxytocin and natriuretic peptide systems in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 2007; 293(1): R267-75.
31. Jankowski M, Bissonauth V, Gao L, Gangal M, Wang D, Danalache B, et al. Anti-inflammatory effect of oxytocin in rat myocardial infarction. Basic Res Cardiol 2010; 105(2): 205-18.
32. Szeto A, Nation DA, Mendez AJ, Dominguez-Bengala J, Brooks LG, Schneiderman N, et al. Oxytocin attenuates NADPHdependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab 2008; 295: E1495-E501.
33. Ondrejcakova M, Ravingerova T, Bakos J, Pancza D, Jezova D. Oxytocin exerts protective effects on in vitro myocardial injury induced by ischemia and reperfusion. Can J Physiol Pharmacol. 2009; 87(2): 137-42.
34. Kobayashi H, Yasuda S, Bao N, Iwasa M, Kawamura I, Yamada Y, et al. Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis. J Cardiovascul Pharmacol 2009; 54(6): 510-9.
35. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al. Postconditioning and protection from reperfusion injury: Where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010; 87(3): 406-23.
36. Alizadeh AM, Faghihi M, Sadeghipour HR, Mohammadghasemi F, Imani A, Houshmand F, et al. Oxytocin protects rat heart against ischemia-reperfusion injury via pathway involving mitochondrial ATP-dependent potassium channel. Peptides 2010; 31(7): 1341-5.
37. Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. Herz 2008; 33(2): 88-100.
38. Alizadeh AM, Faghihi M, Sadeghipour HR, Mohammadghasemi F, Khori V. Role of endogenous oxytocin in cardiac ischemic preconditioning. Regul Pept 2010; 167(1): 86-90.
39. Heusch G, Boengler K, Schulz R. Cardioprotection: Nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118(19): 1915-9.
40. Kasama S, Furuya M, Toyama T, Ichikawa S, Krabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008; 29: 1485-94.
41. Ishii H, Amano T, Matsubara T, Murohara T. Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction. Circulation 2008; 118: 2710-8.
42. van der Heyden MA, Defize LH. Twenty one years of P19 cells: what an embryonal carcinoma cell line taught us about cardiomyocyte differentiation. Cardiovasc Res 2003; 58(2): 292- 302.
43. McBurney MW. P19 embryonal carcinoma cells. Int J Dev Biol 1993;37(1):135-40.
44. Gassanov N, Er F, Zagidullin N, Jankowski M, Gutkowska J, Hoppe UC. Retinoid acid-induced effects on atrial and pacemaker cell differentiation and expression of cardiac ion channels. Differentiation 2008; 76(9): 971-80.
45. Gassanov N, Jankowski M, Danalache B, Wang D, Grygorczyk R, Hoppe UC, et al. Arginine vasopressin-mediated cardiac differentiation: Insights into the role of its receptors and nitric oxide signaling. J Biologic Chemis 2007; 282(15): 11255-65.
46. Gassanov N, Devost D, Danalache B, Noiseux N, Jankowski M, Zingg HH, et al. Functional activity of the carboxyl-terminally extended oxytocin precursor Peptide during cardiac differentiation of embryonic stem cells. Stem Cells 2008; 26(1): 45-54.
47. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biologic Chemis 2004; 279(12): 11384-91.
48. Oyama T, Nagai T, Wada H, Naito AT, Matsuura K, Iwanaga K, et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol 2007; 176(3): 329-41.
49. Martin CM, Meeson AP, Robertson SM, Hawke TJ, Richardson JA, Bates S, et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Developmental Biol 2004; 265(1): 262- 75.
50. Pfister O, Mouquet F, Jain M, Summer R, Helmes M, Fine A, et al. CD31- but Not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation. Circ Res 2005; 97(1): 52-61.
51. Hierlihy AM, Seale P, Lobe CG, Rudnicki MA, Megeney LA. The post-natal heart contains a myocardial stem cell population. FEBS Lett 2002; 530(1-3): 239-43.
52. Mouquet F, Pfister O, Jain M, Oikonomopoulos A, Ngoy S, Summer R, et al. Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. Circ Res 2005; 97(11): 1090-2.
53. Yamahara K, Fukushima S, Coppen SR, Felkin LE, Varela-Carver A, Barton PJ, et al. Heterogeneic nature of adult cardiac side population cells. Biochem BiophysicRes Commun 2008; 371(4): 615-20.
54. Consigny, P., Asongwe, G., Michaels, M.B., Michal, G., Mandrusov, E., Lee J, Lee, J., Ludwing, F., Henckel, J.E., Sciacca, J.J., Bueche, K., Thornton, R.T., Urrabazo, F.A., Wiegand, D. Intracoronary device and method of use thereof. US20070003528 (2007).
55. Meyer, N., Swanson, B., Fiene, S. Cardiomyocyte medium with dialyzed serum. US20110312090 (2011).
56. Stankewicz, C., Riley, M., Beardsley, N., Wang, W.B., Fuhrken, P., Kattman, S. Cardiomyocyte production. US20110097799 (2011).
57. Xu, C., Gold, J.D. Process for making transplantable cardiomyocytes from human embryonic stem cells. US7732199 (2010).
58. Light KC, Grewen KM, Amico JA, Brownley KA, West SG, Hinderliter AL, et al. Oxytocinergic activity is linked to lower blood pressure and vascular resistance during stress in postmenopausal women on estrogen replacement. Horm Behav 2005; 47(5): 540-8.
59. Gutkowska J, Miszkurka M, Danalache B, Gassanov N, Wang D, Jankowski M. Functional arginine vasopressin system in early heart maturation. Am J Physiol Heart Circ Physiol 2007; 293(4): H2262- 70.
60. Amorij, J.-P., Avanti, C., Frijlink, H.W., Hinrichs, W.L.J. Peptide formulations and uses thereof. US20110237508 (2011).
61. Algarsamy, S., Galyean, R., Wisniewski, K., Schteingart, C. Oxytocin analogues. WO2009122285 (2009).
62. Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 2009; 482: 281-94.
63. Shabbir A, Zisa D, Suzuki G, Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: A noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 2009; 296(6): H1888-97.
64. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, et al. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol 2006;291(2): H886-93.
65. Kim YS, Kwon JS, Hong MH, Kim J, Song CH, Jeong MH, et al. Promigratory activity of oxytocin on umbilical cord blood-derived mesenchymal stem cells. Artif Organs 2010; 34(6): 453-61.